Prescribing for chronic heart failure in Europe: Does the country make the difference? A European survey

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 1, 2007, Pages 96-103

  Sturm, H B ^a   van Gilst, W H ^a   Veeger, N ^a   Haaijer Ruskamp, F M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic heart failure; Delivery of health care; Europe; European survey; Prescribing; Primary care; Quality of care

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; CZECH REPUBLIC; DRUG CHOICE; DRUG DOSE REGIMEN; EUROPE; FEMALE; HEALTH CARE SYSTEM; HEART FAILURE; HUMAN; HUNGARY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PATIENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; TURKEY (REPUBLIC); VARIANCE;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DATA COLLECTION; DIGOXIN; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; SEX FACTORS;

EID: 33846525512     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1216     Document Type: Article

References (25)

1. Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J. 1998; 19 suppl P: 2-4.
2. McKee SP, Leslie SJ, LeMaitre JP, Webb DJ, Denvir MA. Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians. Eur J Heart Fail 2003; 5: 549-555.
3. Freeman AC, Sweeney K. Why general practitioners do not implement evidence: qualitative study. Br Med J 2001; 323: 1100-1102.
4. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360: 1631-1639.
5. Kotseva K, Wood D, De Backer G, et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
6. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-474.
7. Stewart S, Blue L, Capewell S, Horowitz JD, McMurray JJ. Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. Eur J Heart Fail 2001; 3: 249-255.
8. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261-270.
9. Massie BM, Cleland JG, Armstrong PW, et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (AThAS) Trial Investigators. J Card Fail 1998; 4: 3-8.
10. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Calif RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004; 148: 122-128.
11. van Veldhuisen DJ, Charlesworth A, Crijns HJ, Lie KI, Hampton JR. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J 1999; 20: 666-672.
12. Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004; 6: 663-668.
13. Sturm HB, Haaijer-Ruskamp FM, Veeger NJ, Balje-Volkers C, Swedberg K, van Gilst WH. The relevance of comorbidities for heart failure treatment in primary care. A European Survey Eur J Heart Fail. 2006 Jan; 8(1): 31-37.
14. The treatment of heart failure. The task force on heart failure of the European Society of Cardiology. Eur Heart J 1997; 18: 736-753.
15. Brink-Muinen A, Verhaak PF, Bensing JM, et al. Communication in general practice: differences between European countries. Fam Pract 2003; 20: 478-485.
16. Gorecka K, Vlcek J, Walker R. Comparison of utilization of cardiovascular drugs in the Czech Republic and in Wales. Vnitr Lek 2003; 49: 592-597.
17. Kooiker S, van der Wijst L. Europeans and their medicines: a cultural approach to the utilization of pharmaceuticals. Social Cultural Planning Office of the Netherlands, GfK Panelservices Benelux, 2003.
18. Deschepper R, Vander Stichele RH, Haaijer-Ruskamp FM. Cross-cultural differences in lay attitudes and utilisation of antibiotics in a Belgian and a Dutch city. Patient Educ Couns 2002; 48: 161-169.
19. Hassell K, Atella V, Schafheutle EI, Weiss MC, Noyce PR. Cost to the patient or cost to the healthcare system? Which one matters the most for GP prescribing decisions? A UK-Italy comparison. Eur J Public Health 2003; 13: 18-23.
20. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003; 349: 2224-2232.
21. Chaix-Couturier C, Durand-Zaleski I, Jolly D, Durieux P. Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues. Int J Qual Health Care 2000; 12: 133-142.
22. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004; 42: 653-660.
23. Krumholz HM, Baker DW, Ashton CM, et al. Evaluating quality of care for patients with heart failure. Circulation 2000; 101: E122-E140.
24. Denig P, Schaars CF, Kasje WN, Haaijer-Ruskamp FM. Patient, doctor, and organisational factors affecting hypertension management in patients with type 2 diabetes. Br J Clin Pharmacol 2004; 57: 357.
25. Sturm HB, van Gilst WH, Swedberg K, Hobbs FD, Haaijer-Ruskamp FM. Heart failure guidelines and prescribing in primary care across Europe. BMC Health Serv Res. 2005 Aug. 30, 5.57 PMID. 16131393 [Pub Med indeed for MEDLINE].